We are live on ! Find out more
RNAZ icon

TransCode Therapeutics
RNAZ

8 hedge funds and large institutions have $208K invested in TransCode Therapeutics in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.16% more ownership

Funds ownership: 3.37% → 3.53% (+0.16%)

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

22% less capital invested

Capital invested by funds: $266K → $208K (-$57.6K)

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
YAG
Yorkville Advisors Global
New Jersey
+$134K
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.8K
3
TRCT
Tower Research Capital (TRC)
New York
+$3.05K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$110K
2
UBS Group
UBS Group
Switzerland
-$36.8K

RNAZ Hedge Fund Activity: Q2 2026 in Review

8 of the 8,339 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q2 2026, worth a combined $208K — down 22% from $266K a quarter earlier.

Fund positioning in RNAZ was balanced in Q2 2026: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Yorkville Advisors Global, opening a new position worth an estimated $134K. The largest seller was Geode Capital Management, exiting entirely with an estimated $110K sold.

  • 8 institutional investors held TransCode Therapeutics (RNAZ) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $208K of TransCode Therapeutics stock for Q2 2026, down 22% quarter-over-quarter.
  • 2 funds opened new TransCode Therapeutics positions in Q2 2026 and 2 closed out, a net change of 0 holders.
  • The largest TransCode Therapeutics buyer in Q2 2026 was Yorkville Advisors Global, an estimated $134K added.
  • The largest TransCode Therapeutics seller in Q2 2026 was Geode Capital Management, an estimated $110K sold.

Based on aggregated 13F filings for Q2 2026.